Multiomic Single‐Cell Sequencing Identifies <i>BCR::ABL1</i> as an Acquired Resistance Mechanism in <i>FLT3+</i> <scp>AML</scp>
BCR::ABL1 acquisition is an emerging but poorly characterized resistance mechanism in FLT3-mutated AML. Using multiomic single-cell DNA sequencing, we characterized clonal evolution in a patient with FLT3-ITD AML who acquired BCR::ABL1 with FLT3 inhibitor resistance. Phylogenetic reconstruction confirmed BCR::ABL1 as a branch event co-occurring with FLT3-ITD and restricted to specific blast populations, supporting BCR::ABL1 acquisition as a resistance mechanism.
Authors
- Andrew Koh
- Elaine Tran (ORCID: https://orcid.org/0009-0000-5370-7788)
- Lan Beppu (ORCID: https://orcid.org/0000-0002-0401-1159)
- Dalia Dhingra
- Adam Sciambi (ORCID: https://orcid.org/0000-0002-6899-4449)
- Saurabh Gulati
- Olga Sala-Torra
- Vanessa E. Kennedy
- Catherine C. Smith
- Jerald P. Radich
- Cheryl A. C. Peretz
Institutions
- University of California, San Francisco (US)
- Fred Hutch Cancer Center (US)
- Mission Bio (United States) (US)
- Stanford University (US)
Publication Details
- Journal
- European Journal Of Haematology
- Published
- 2026-04-27
- DOI
- https://doi.org/10.1111/ejh.70207
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00